Lupin Receives USFDA Form 483 With Three Observations For Somerset Facility
Lupin has received a Form 483 from the USFDA containing three observations for its Somerset, New Jersey manufacturing facility following an inspection conducted from April 13-17, 2026. The pharmaceutical company disclosed this regulatory development to stock exchanges and committed to addressing the compliance observations within the required timeframe while maintaining cGMP standards.
*this image is generated using AI for illustrative purposes only.
Lupin has received a Form 483 from the US Food and Drug Administration (USFDA) containing three observations for its manufacturing facility in Somerset, New Jersey, USA. The pharmaceutical company disclosed this regulatory development through an official communication to stock exchanges, highlighting compliance matters that require attention at one of its key US manufacturing sites.
Inspection Timeline and Details
The USFDA conducted its inspection of Lupin's Somerset, New Jersey manufacturing facility from April 13, 2026 to April 17, 2026. Following the completion of the inspection, the regulatory authority issued Form 483 documenting three specific observations that need to be addressed by the company.
| Parameter: | Details |
|---|---|
| Facility Location: | Somerset, New Jersey, USA |
| Inspection Period: | April 13-17, 2026 |
| Regulatory Authority: | USFDA |
| Document Type: | Form 483 |
| Number of Observations: | Three |
Regulatory Disclosure Requirements
Lupin made this disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the disclosure with both the National Stock Exchange of India Limited and BSE Limited, ensuring transparency with stakeholders regarding this regulatory matter.
Company Response and Commitment
Lupin has committed to addressing the observations identified during the inspection and will respond to the USFDA within the stipulated timeframe. The company emphasized its commitment to maintaining compliance with current Good Manufacturing Practice (cGMP) standards across all its facilities. This response demonstrates the company's proactive approach to regulatory compliance and quality assurance.
Understanding Form 483 Impact
Form 483 serves as an official communication tool between the FDA and pharmaceutical companies, outlining observations where inspectors believe the facility may not be in full compliance with FDA regulations or cGMP standards. The Somerset facility represents an important part of Lupin's manufacturing infrastructure in the United States, serving one of the largest pharmaceutical markets globally.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.74% | -0.16% | -0.47% | +18.92% | +15.05% | +112.10% |
Will the three FDA observations lead to any production delays or supply chain disruptions for Lupin's US market products?
How might this Form 483 affect Lupin's pending drug approvals or new product launches from the Somerset facility?
Could these compliance issues impact Lupin's ability to secure new manufacturing contracts with US pharmaceutical partners?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
